AU2010204445B2 - Treatment of soft tissue injury using hyaluronic acid and botulinum toxin - Google Patents

Treatment of soft tissue injury using hyaluronic acid and botulinum toxin Download PDF

Info

Publication number
AU2010204445B2
AU2010204445B2 AU2010204445A AU2010204445A AU2010204445B2 AU 2010204445 B2 AU2010204445 B2 AU 2010204445B2 AU 2010204445 A AU2010204445 A AU 2010204445A AU 2010204445 A AU2010204445 A AU 2010204445A AU 2010204445 B2 AU2010204445 B2 AU 2010204445B2
Authority
AU
Australia
Prior art keywords
soft tissue
botulinum toxin
peri
treatment
sprain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010204445A
Other languages
English (en)
Other versions
AU2010204445A1 (en
Inventor
Robert John Petrella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
2405871 Ontario Inc
Original Assignee
2405871 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42311846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010204445(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 2405871 Ontario Inc filed Critical 2405871 Ontario Inc
Publication of AU2010204445A1 publication Critical patent/AU2010204445A1/en
Application granted granted Critical
Publication of AU2010204445B2 publication Critical patent/AU2010204445B2/en
Assigned to 2405871 ONTARIO INC. reassignment 2405871 ONTARIO INC. Request for Assignment Assignors: PETRELLA, ROBERT
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010204445A 2009-01-07 2010-01-06 Treatment of soft tissue injury using hyaluronic acid and botulinum toxin Active AU2010204445B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14294109P 2009-01-07 2009-01-07
US61/142,941 2009-01-07
PCT/CA2010/000008 WO2010078648A1 (en) 2009-01-07 2010-01-06 Treatment of soft tissue injury using hyaluronic acid and botulinum toxin

Publications (2)

Publication Number Publication Date
AU2010204445A1 AU2010204445A1 (en) 2011-07-28
AU2010204445B2 true AU2010204445B2 (en) 2015-09-03

Family

ID=42311846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010204445A Active AU2010204445B2 (en) 2009-01-07 2010-01-06 Treatment of soft tissue injury using hyaluronic acid and botulinum toxin

Country Status (7)

Country Link
US (1) US9072779B2 (enExample)
EP (1) EP2381956B9 (enExample)
JP (2) JP5688031B2 (enExample)
AU (1) AU2010204445B2 (enExample)
CA (1) CA2749034C (enExample)
ES (1) ES2538835T3 (enExample)
WO (1) WO2010078648A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
PT3019177T (pt) * 2013-07-10 2020-12-30 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2015115113A1 (ja) * 2014-01-31 2015-08-06 テルモ株式会社 穿刺補助器具および穿刺器具セット
ES2871199T3 (es) 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
US11969461B2 (en) * 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
KR20190142404A (ko) * 2017-05-24 2019-12-26 주식회사 에이티지씨 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578250A1 (en) * 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
WO2006084353A1 (en) * 2005-02-14 2006-08-17 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
WO2006116302A2 (en) * 2005-04-22 2006-11-02 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
CA2510058C (en) 2002-12-20 2010-03-16 Botulinum Toxin Research Associates, Inc. Improved pharmaceutical botulinum toxin compositions
JP2007507431A (ja) 2003-10-09 2007-03-29 ロバート・ジョン・ペトレラ ヒアルロン酸を使用する急性及び過用性の捻挫及び筋違いの治療方法
US20090185489A1 (en) * 2004-07-22 2009-07-23 Marco Ruffini Scheduling the transmission of messages on a broadcast channel of an ad-hoc network dependent on the usage of this channel
FR2896693B1 (fr) 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578250A1 (en) * 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
WO2006084353A1 (en) * 2005-02-14 2006-08-17 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
WO2006116302A2 (en) * 2005-04-22 2006-11-02 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KLEIN A.W. et al., "Hyaluronic Acid illers and Botulinum Toxin Type A: Rationale for Their Individual and Combined Use for Injectable Facial Rejuvenation", Plast. Reconstr. Surg. (Suppl.), 2007, pages 81S-88S *

Also Published As

Publication number Publication date
US9072779B2 (en) 2015-07-07
WO2010078648A1 (en) 2010-07-15
EP2381956B1 (en) 2015-04-22
CA2749034A1 (en) 2010-07-15
EP2381956A1 (en) 2011-11-02
EP2381956A4 (en) 2013-01-02
JP2014208705A (ja) 2014-11-06
AU2010204445A1 (en) 2011-07-28
JP2012514579A (ja) 2012-06-28
EP2381956B9 (en) 2016-11-23
JP5688031B2 (ja) 2015-03-25
CA2749034C (en) 2019-01-15
US20100172940A1 (en) 2010-07-08
ES2538835T3 (es) 2015-06-24

Similar Documents

Publication Publication Date Title
AU2010204445B2 (en) Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
Scale et al. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study
JP2016185989A (ja) ヒアルロン酸を使用する急性及び過用性の捻挫及び筋違いの治療方法
Fuchs et al. Intra-articular hyaluronic acid compared with corticoid injections for the treatment of rhizarthrosis
Pavelka et al. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study
Witteveen et al. A prospective multi-centre, open study of the safety and efficacy of hylan GF 20 (Synvisc®) in patients with symptomatic ankle (talo-crural) osteoarthritis
Lee et al. Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial
Oh et al. Comparative analysis of intra-articular injection of steroid and/or sodium hyaluronate in adhesive capsulitis: prospective, double-blind, randomized, placebo-controlled study
Yilmaz The evaluation of the effectiveness of intra-articular steroid, tenoxicam, and combined steroid–tenoxicam injections in the treatment of patients with knee osteoarthritis
Lee et al. Effect of hypertonic saline in intra-articular hydraulic distension for adhesive capsulitis
Mei-Dan et al. Treatment of osteoarthritis of the ankle by intra-articular injections of hyaluronic acid: a prospective study
Michel et al. Viscosupplementation in symptomatic severe hip osteoarthritis: a review of the literature and report on 60 patients
Zorzi et al. A new hydrogel for the conservative treatment of meniscal lesions: a randomized controlled study
Benke et al. Viscosupplementation treatment of arthritis pain
Witteveen et al. The optimal injection technique for the osteoarthritic ankle: a randomized, cross-over trial
Petrella et al. Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
Stitik et al. Synvisc®® in knee osteoarthritis
Lynen Treatment of chronic tendinopathies with peritendinous hyaluronan injections under sonographic guidance—an interventional, prospective, single-arm, multicenter study, Dtsch
ÖRÜCÜ ATAR et al. Ultrasound-Guided Hydrodissection Combined with Peripheral Nerve Block for the Treatment of Post-Traumatic Knee Stiffness.
PIOVaN A new hydrogel for the conservative treatment of meniscal lesions: a randomized controlled study
WO2016092377A2 (ru) Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов, её применение и способ лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника
Sun et al. Hyaluronate for the Treatment of Ankle Osteoarthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: 2405871 ONTARIO INC.

Free format text: FORMER OWNER(S): PETRELLA, ROBERT